HiFiBiO Therapeutics

OverviewSuggest Edit

HiFiBiO Therapeutics is a biotherapeutics company. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies. It allows discovering and advancing a pipeline of antibody drugs to treat cancer and autoimmune disorders.

TypePrivate
Founded2013
HQParis, FR
Websitehifibio.com

Latest Updates

Employees (est.) (Sept 2021)77(+7%)
Cybersecurity ratingAMore

Key People/Management at HiFiBiO Therapeutics

Liang Schweizer

Liang Schweizer

Chief Executive Officer & Chief Scientific Officer
Jeff He

Jeff He

Chief Operating Officer
Xuqiong Wu

Xuqiong Wu

General Counsel
Show more

HiFiBiO Therapeutics Office Locations

HiFiBiO Therapeutics has offices in Paris, Cambridge and Shanghai
Paris, FR (HQ)
29 Rue du Faubourg Saint-Jacques
Shanghai, CN
1077 Zhangheng Rd, Pudong Xinqu
Cambridge, MA, US
237 Putnam Ave
Show all (3)

HiFiBiO Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

HiFiBiO Therapeutics total Funding

$179.5 m

HiFiBiO Therapeutics latest funding size

$75 m

Time since last funding

3 months ago

HiFiBiO Therapeutics investors

HiFiBiO Therapeutics's latest funding round in June 2021 was reported to be $75 m. In total, HiFiBiO Therapeutics has raised $179.5 m
Show all financial metrics

HiFiBiO Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

HiFiBiO Therapeutics Online and Social Media Presence

Embed Graph

HiFiBiO Therapeutics Blogs

HiFiBiO Therapeutics Contributes to CoVIC-Led Analysis on the Identification of Distinct Epitope Communities Among SARS-CoV-2 Spike Antibodies Efficacious Against Variants of Concern

CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, PARIS – September 23, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and single-cell science, today announced a publication in Science in collaboration with the Coronavirus Immunotherapy Con…

HiFiBiO Strengthens its Senior Leadership Team in Preparation for First-in-Human Studies of Two Lead Immunoncology Programs and a Sustainable Pipeline

(From left to right) Christos Hatzis, PhD, Vice President, Head of Clinical Pharmacogenomics, John Pallante, Vice President, Head of Clinical Operations, and Edward Rocnik, PhD, Executive Director, Head of CMC have joined the company’s senior leadership team. CAMBRIDGE, Mass. – August 9, 2021 – HiFi…

FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

FibroGen Exclusively Licenses HiFiBiO’s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs Transformative Transaction for FibroGen’s Early-stage Pipeline HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B in Additional Milestone Payments Across All T…

HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS™ Approach in the Clinic

Latest funding led by Mirae Asset Financial Group and joined by B Capital Group, Sherpa, and other new investors together with existing investors such as IDG and Sequoia CAMBRIDGE, Mass., HONG KONG, HANGZHOU, SHANGHAI, and PARIS, – June 14, 2021 – HiFiBiO Therapeutics, a multinational biotechnology …

HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy

HiFiBio Therapeutics announced a publication in Science Advances with its collaborators at Nankai University, ShanghaiTech University, and Jiao Tong University about the development of a high-throughput droplet-based approach to identify novel antibodies with functional readouts beyond simple bindin…

HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody

HFB30132A possesses differentiated properties providing strong potential for COVID-19 treatment and prevention HONG KONG – May 11, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and single-cell science, today announced a publication in N…
Show more

HiFiBiO Therapeutics Frequently Asked Questions

  • When was HiFiBiO Therapeutics founded?

    HiFiBiO Therapeutics was founded in 2013.

  • Who are HiFiBiO Therapeutics key executives?

    HiFiBiO Therapeutics's key executives are Liang Schweizer, Jeff He and Xuqiong Wu.

  • How many employees does HiFiBiO Therapeutics have?

    HiFiBiO Therapeutics has 77 employees.

  • Who are HiFiBiO Therapeutics competitors?

    Competitors of HiFiBiO Therapeutics include Sphere Fluidics, BioFactura and Respivant Sciences.

  • Where is HiFiBiO Therapeutics headquarters?

    HiFiBiO Therapeutics headquarters is located at 29 Rue du Faubourg Saint-Jacques, Paris.

  • Where are HiFiBiO Therapeutics offices?

    HiFiBiO Therapeutics has offices in Paris, Cambridge and Shanghai.

  • How many offices does HiFiBiO Therapeutics have?

    HiFiBiO Therapeutics has 3 offices.